NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that its lead compound, Plinabulin, will be presented in two posters at the upcoming 16th World Conference on Lung Cancer (WCLC), which is hosted by the International Association for the Study of Lung Cancer (IASLC), and taking place September 6-9, 2015 in Denver, CO.
Abstract 1505 will present results of follow-up analysis of data from the Phase 2 study of Plinabulin combined with docetaxel in patients with advanced NSCLC, and Abstract 1498, an update on the design of the upcoming Phase 3 clinical trial of Plinabulin. The presentations will be held on Tuesday and Wednesday, September 8 and 9, 2015. The full logistical details of the presentations are provided below.
- Abstract #1505 / P3.01-057: Randomized Phase 2 Study of Plinabulin and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer – Mechanism-Based Efficacy Analyses
First / Presenting Author: Lyudmila Bazhenova, MD Poster Session: Treatment of Advanced Diseases – NSCLC Date, Time: Wed, September 9; 9:30 a.m. – 4:30 p.m. MT Location: Exhibit Hall (Hall B+C)
- Abstract #1498 / P2.01-101: Randomized Phase 3 Trial of Docetaxel + Plinabulin Compared to Docetaxel in Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion
First / Presenting Author: Lyudmila Bazhenova, MD Poster Session: Treatment of Advanced Diseases – NSCLC Date, Time: Tue, September 8; 9:30 a.m. – 4:30 p.m. MT Location: Exhibit Hall (Hall B+C)
Dr. Lan Huang, Co-Founder & CEO of BeyondSpring Pharmaceuticals, commented, "We are excited to present the global Phase 3 study and to update the lung cancer research community with our new observations and progress in clinical development of Plinabulin at the upcoming WCLC 2015, the world's largest meeting dedicated to lung and thoracic tumors. We are pleased to have initiated this phase 3 study with the first clinical site at University of California at San Diego and Dr. Bazhenova as our principal investigator. Based on its multiple mechanisms of action that target and alter the tumor microenvironment, we believe that Plinabulin has significant potential to extend the lives of NSCLC patients."
About BeyondSpring Pharmaceuticals
BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase 3-ready cancer therapeutic initially targeting non-small-cell lung cancer (NSCLC). Led by an expert management team consisting of pharmaceutical industry veterans from the U.S. and China, the Company is well positioned to further advance lead product candidate, Plinabulin. For more information, visit www.beyondspringpharma.com.